Fucidin

Poland
Brand name Fucidin
Form ointment
Active substance / Dosage
Prescription type Prescription only
ATC code
Registration number 100386031
Manufacturer LEO Pharma A/S
Fucidin ointment

Package leaflet: Information for the patient

Warning! Keep this leaflet! Information on the immediate packaging is in a foreign language.
Fucidin
20 mg/g, ointment
Fusidic acid sodium salt
Please read carefully all the information in this leaflet before using the medicine, as it contains
important information for the patient.

  • Keep this leaflet, so that you can read it again if necessary.
  • If you have any doubts, please consult your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for a specific individual. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
  • If you experience any adverse reactions, including any adverse reactions not listed in this leaflet, inform your doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet:

  1. What Fucidin ointment is and what it is used for
  2. Important information before using Fucidin ointment
  3. How to use Fucidin ointment
  4. Possible side effects
  5. How to store Fucidin ointment
  6. Contents of the pack and other information

1. What Fucidin ointment is and what it is used for

Fucidin is an ointment for topical use. The active substance is fusidic acid sodium salt – an antibiotic with antibacterial activity. Fusidic acid sodium salt acts against certain Gram-positive bacteria. Staphylococci are particularly sensitive to its action.
Fucidin ointment is indicated for the topical treatment of bacterial skin infections caused by microorganisms sensitive to fusidic acid. The main indications are: impetigo, folliculitis, furunculosis, infected sebaceous glands, paronychia, and carbuncle.

2. Important information before using Fucidin ointment

When not to use Fucidin ointment

  • if the patient is allergic to sodium fusidate or to any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Avoid contact of the medicine with eyes and mucous membranes, as it may cause irritation of the conjunctiva and mucous membranes.

Other medicines and Fucidin ointment
No studies have been conducted on interactions with other medicines.
Tell your doctor or pharmacist about all medicines the patient is currently using, has recently used, or plans to use.

Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor before using this medicine.
Fucidin ointment should not be used on the breasts during breastfeeding.

Driving and operating machinery
Fucidin ointment has no effect or has a negligible effect on the ability to drive motor vehicles and operate mechanical devices or psycho-physical performance.

Fucidin ointment contains lanolin, cetyl alcohol, and butylhydroxytoluene (E 321).
Lanolin and cetyl alcohol may cause local skin reactions (e.g. contact dermatitis).
Butylhydroxytoluene (E 321) may cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes.

3. How to use Fucidin, ointment

This medicine should always be used as directed by the physician. In case of doubt, consult the
physician or pharmacist.
The medicine is intended for topical application to the skin.
The medicine is usually applied to affected skin areas 2 to 3 times daily for 7 days.
Use of a higher than recommended dose of the medicine
No cases of overdose have been reported when the medicine is used according to indications and
recommended dosage.
However, if discomfort occurs after overdose, contact a physician.
Missed application of Fucidin ointment
Do not apply a double dose to make up for a missed application.
Continue treatment according to the previously established schedule.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Severe adverse reactions may occur (in 1 patient out of 1000), such as swelling of the skin and mucous membranes of the face, oral cavity and throat. If these occur, contact your doctor immediately.
Other adverse reactions include:
Uncommon (may affect up to 1 in 100 people)

  • irritation at the site of application,
  • skin inflammation, rash,
  • itching,
  • rash,
  • redness,
  • burning sensation.

Rare (may affect up to 1 in 1000 people)

  • allergic reactions,
  • conjunctivitis,
  • urticaria, skin blisters,
  • angioedema.

Reporting of adverse reactions
If any adverse effects occur, including any adverse effects not listed in this leaflet, inform your doctor, pharmacist or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: + 48 22 49 21 301, fax: + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Fucidin ointment

No special storage requirements.
The shelf life after first opening the tube – 90 days.
Keep the medicine out of the sight and reach of children.
Do not use the medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer in use. This helps protect the environment.

6. Contents of the package and other information

What Fucidin ointment contains
Active substance: fusidic acid sodium salt.
Each gram of ointment contains 20 mg of fusidic acid sodium salt.
Other components: lanolin (contains butylhydroxytoluene (E 321)), cetyl alcohol,
liquid paraffin (contains all-rac-ɑ-Tocopherol), white soft paraffin (contains all-rac-ɑ-Tocopherol).

What the packaging looks like and contents of the pack
An aluminium tube containing 15 g of ointment, placed in a cardboard carton.
For more detailed information, please contact the marketing authorisation holder or the parallel importer.

Marketing authorisation holder in the Czech Republic, country of export:
LEO Pharma A/S
Industriparken 55
2750 Ballerup
Denmark

Manufacturer:
LEO Laboratories Ltd.
285 Cashel Road
Dublin 12
Ireland

Parallel importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Poland

Repackaged in:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Poland

Marketing authorisation number in the Czech Republic, country of export: 46/284/97-C
Parallel import authorisation number: 108/17